

# THE ALAN MOREMENT MEMORIAL FUND

England & Wales · Charity number 1091915

## Details

---

**Other names** AMMF

**Status** Registered

**Legal form** Other

**Registered** 2002-05-08

**Register** [View on the Charity Commission register](#)

## Contact

---

**Address** Enterprise House  
Bassingbourn Road  
Stansted  
Essex  
CM24 1QW

**Phone** 01279661479

**Email** [info@ammf.org.uk](mailto:info@ammf.org.uk)

**Website** [www.ammf.org.uk](http://www.ammf.org.uk)

## Activities

---

**Objects:** THE TRUSTEES SHALL HOLD THE TRUST FUND AND ITS INCOME UPON TRUST FOR THE FOLLOWING OBJECTS ("THE OBJECTS"):FOR THE PUBLIC BENEFIT, THE ADVANCEMENT OF HEALTH, INCLUDING BY RAISING THE AWARENESS AND UNDERSTANDING OF CHOLANGIOCARCINOMA (BILE DUCT CANCER) AND RELATED CANCERS AND CONDITIONS INCLUDING THROUGH THE:PROMOTION OF RESEARCH INTO CAUSES, TREATMENTS AND CURES; ANDDISSEMINATION OF INFORMATION TO PATIENTS, CARERS AND HEALTH CARE PROFESSIONALS.

**Activities:** AMMF is dedicated to raising the awareness of cholangiocarcinoma (bile duct cancer), supplying information to those who need it, and raising funds to support specialised research teams in their work into the causes, methods of earlier diagnosis and treatments of this disease.

## Classification

- **How:** Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Other Charities Or Voluntary Bodies

## Geography

- **Area of benefit:** ESSEX
- Northern Ireland
- Scotland
- Throughout England And Wales

## Finances

Period end	Income	Expenditure	Assets	Employees
2025-01-31	£0	£0	-	-
2024-01-31	£0	£0	-	-
2023-01-31	£131,639	£255,377	-	-
2022-01-31	£836,350	£629,851	£626,703	3
2021-01-31	£455,659	£398,952	-	-

## Trustees

Name	Role	Appointed
Noel Corrigan FORS	Chair	2014-06-01
Gillian Corrigan		2015-10-30
HARRY CORRIGAN		
TOM MOREMENT		

**THE ALAN MOREMENT MEMORIAL FUND**

England & Wales - Charity number 1091915

---

# Accounts

---

---

**AMMF**

**THE ALAN MOREMENT MEMORIAL FUND**

---

**UNAUDITED**

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 JANUARY 2023**

---

**ALAN MOREMENT MEMORIAL FUND**

---

**CONTENTS**

---

	Page
<b>Reference and Administrative Details of the Charity, its Trustees and Advisers</b>	1
<b>Trustees' Report</b>	2
<b>Trustees' Responsibilities Statement</b>	3
<b>Independent Examiner's Report</b>	4 - 6
<b>Statement of Financial Activities</b>	7
<b>Balance Sheet</b>	8
<b>Notes to the Financial Statements</b>	9 - 19

---

**ALAN MOREMENT MEMORIAL FUND**

---

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS  
FOR THE YEAR ENDED 31 JANUARY 2023**

---

<b>Trustees</b>	N Corrigan, Chair G C Corrigan T P Morement H Corrigan
<b>Charity registered number</b>	1091915
<b>Principal office</b>	Enterprise House Bassingbourn Road Stansted Essex CM24 1QW
<b>Accountants</b>	Haslers Chartered Accountants Old Station Road Loughton Essex IG10 4PL

---

## ALAN MOREMENT MEMORIAL FUND

---

### TRUSTEES' REPORT FOR THE YEAR ENDED 31 JANUARY 2023

---

The trustees present their report with the financial statements of the charity for the year ended 31 January 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

In 2002, AMMF was registered with the Charity Commission with the name, The Alan Morement Memorial Fund (registered charity no 1091915), and with the working title, AMMF.

Because of the continuing growth of the charity, AMMF's trustees decided that the charity should transition as a legal entity from its existing unincorporated registered charity status to that of a Charitable Incorporated Organisation (CIO). This involved lengthy work with the Charity Commission, and the new CIO status was approved on 01 June, 2022. At that point the work and all assets of the original charity passed to the new CIO charity.

As a CIO, AMMF has a new registered number with the Charity Commission. The original charity and its registered number 1091915 will always remain in existence, with all records submitted to the Charity Commission still available on the Commission's website, but this entity will now remain in the background.

**The new CIO is officially known as: AMMF – The Cholangiocarcinoma Charity, with the registered number: 1198095.**

#### OBJECTIVES AND AIMS

The aims and objectives of AMMF remain unchanged and the charity's work has and will continue seamlessly and without interruption, full details can be found in financial statements for the above.

Approved by order of the members of the board of Trustees on 3 November 2023 and signed on their behalf by:



**N Corrigan**  
(Chair of Trustees)

---

## ALAN MOREMENT MEMORIAL FUND

---

### STATEMENT OF TRUSTEES' RESPONSIBILITIES FOR THE YEAR ENDED 31 JANUARY 2023

---

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on 3 November 2023 and signed on its behalf by:



**N Corrigan**  
(Chair of Trustees)

---

**ALAN MOREMENT MEMORIAL FUND**

---

**INDEPENDENT EXAMINER'S REPORT  
FOR THE YEAR ENDED 31 JANUARY 2023**

---

**Independent Examiner's Report to the Trustees of Alan Morement Memorial Fund ('the Charity')**

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 January 2023.

**Responsibilities and Basis of Report**

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

---

**ALAN MOREMENT MEMORIAL FUND**

---

**INDEPENDENT EXAMINER'S REPORT (CONTINUED)  
FOR THE YEAR ENDED 31 JANUARY 2023**

---

**Independent Examiner's Statement**

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ACCA, which is one of the listed bodies.

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

---

ALAN MOREMENT MEMORIAL FUND

---

INDEPENDENT EXAMINER'S REPORT (CONTINUED)  
FOR THE YEAR ENDED 31 JANUARY 2023

---

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed:



Dated: 3 November 2023

P Thain

**Haslers**

Chartered Accountants  
Old Station Road  
Loughton  
Essex  
IG10 4PL

---

**ALAN MOREMENT MEMORIAL FUND**

---

**STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 JANUARY 2023**

---

	Note	Restricted funds 2023 £	Unrestricted funds 2023 £	Total funds 2023 £	<i>Total funds 2022 £</i>
<b>Income from:</b>					
Donations and legacies	3	131,639	251,128	382,767	821,649
Other trading activities	4	-	-	-	14,055
Investments	5	-	-	-	646
<b>Total income</b>		<u>131,639</u>	<u>251,128</u>	<u>382,767</u>	<u>836,350</u>
<b>Expenditure on:</b>					
Raising funds		-	1,305	1,305	2,276
Charitable activities	6	255,377	752,688	1,008,065	627,575
<b>Total expenditure</b>		<u>255,377</u>	<u>753,993</u>	<u>1,009,370</u>	<u>629,851</u>
<b>Net movement in funds</b>		<u>(123,738)</u>	<u>(502,865)</u>	<u>(626,603)</u>	<u>206,499</u>
<b>Reconciliation of funds:</b>					
Total funds brought forward		123,738	502,965	626,703	420,204
Net movement in funds		(123,738)	(502,865)	(626,603)	206,499
<b>Total funds carried forward</b>		<u>-</u>	<u>100</u>	<u>100</u>	<u>626,703</u>

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 9 to 19 form part of these financial statements.

---

ALAN MOREMENT MEMORIAL FUND

---

BALANCE SHEET  
AS AT 31 JANUARY 2023

---

	Note		2023 £	2022 £
<b>Fixed assets</b>			<u>-</u>	<u>-</u>
<b>Current assets</b>				
Stocks	10	-	7,122	
Debtors	11	-	12,144	
Cash at bank and in hand		<b>100</b>	733,883	
		<u>100</u>	<u>753,149</u>	
Creditors: amounts falling due within one year	12	-	(126,446)	
<b>Net current assets</b>			<u>100</u>	<u>626,703</u>
<b>Total assets less current liabilities</b>			<u>100</u>	<u>626,703</u>
<b>Total net assets</b>			<u>100</u>	<u>626,703</u>
<b>Charity funds</b>				
Restricted funds	13	-		123,738
Unrestricted funds	13	<b>100</b>		502,965
<b>Total funds</b>			<u>100</u>	<u>626,703</u>

The financial statements were approved and authorised for issue by the Trustees on 03 November 2023 and signed on their behalf by:



**N Corrigan**  
(Chair of Trustees)

The notes on pages 9 to 19 form part of these financial statements.

---

## ALAN MOREMENT MEMORIAL FUND

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2023

---

#### 1. General information

Alan Morement Memorial Fund is an unincorporated charity, domiciled in England and Wales, registration number 1091915. The registered office is Enterprise House, Bassingbourn Road, Stansted, Essex, CM24 1QW and the principal place of business is throughout the United Kingdom. The principal aim of the charity is to raise awareness of cholangiocarcinoma (bile duct cancer), supply information to those who need it, and to raise funds to support specialised research teams in their work into the causes, methods of earlier diagnosis and treatments of this disease.

#### 2. Accounting policies

##### 2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Alan Morement Memorial Fund meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

##### 2.2 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

##### 2.3 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

---

## ALAN MOREMENT MEMORIAL FUND

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2023

---

#### 2. Accounting policies (continued)

##### 2.3 Expenditure (continued)

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

##### 2.4 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

##### 2.5 Stocks

Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.

##### 2.6 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

##### 2.7 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

##### 2.8 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

##### 2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

---

**ALAN MOREMENT MEMORIAL FUND**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2023**

---

**3. Income from donations and legacies**

	<b>Restricted funds 2023 £</b>	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>	<b>Total funds 2022 £</b>
Donations	131,639	251,128	<b>382,767</b>	821,649
<i>Total 2022</i>	<u>140,618</u>	<u>681,031</u>	<u>821,649</u>	

**4. Income from other trading activities**

**Income from non charitable trading activities**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>	<b>Total funds 2022 £</b>
Shop income	-	-	14,055
	<u>-</u>	<u>-</u>	<u>14,055</u>

**5. Investment income**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>	<b>Total funds 2022 £</b>
Deposit account interest	-	-	646
	<u>-</u>	<u>-</u>	<u>646</u>
<i>Total 2022</i>	<u>646</u>	<u>646</u>	

---

**ALAN MOREMENT MEMORIAL FUND**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2023**

---

**6. Analysis of expenditure on charitable activities**

**Summary by fund type**

	<b>Restricted funds 2023 £</b>	<b>Unrestricted funds 2023 £</b>	<b>Total 2023 £</b>	<i>Total 2022 £</i>
Costs	255,377	752,688	<b>1,008,065</b>	627,575
	<u>255,377</u>	<u>752,688</u>	<u>1,008,065</u>	
<i>Total 2022</i>	<u>38,000</u>	<u>589,575</u>	<u>627,575</u>	

**7. Analysis of expenditure by activities**

	<b>Activities undertaken directly 2023 £</b>	<b>Support costs 2023 £</b>	<b>Total funds 2023 £</b>	<i>Total funds 2022 £</i>
Costs	11,991	996,074	<b>1,008,065</b>	627,575
	<u>11,991</u>	<u>996,074</u>	<u>1,008,065</u>	
<i>Total 2022</i>	<u>232,087</u>	<u>395,488</u>	<u>627,575</u>	

**Analysis of direct costs**

	<b>Total funds 2023 £</b>	<i>Total funds 2022 £</i>
Grants to institutions	<b>1,208</b>	194,087
European Website costs	-	37,790
European Conference 2022 costs	-	210
Workshops	<b>10,783</b>	-
	<u>11,991</u>	<u>232,087</u>

---

**ALAN MOREMENT MEMORIAL FUND**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2023**

---

**7. Analysis of expenditure by activities (continued)**

**Analysis of support costs**

	<b>Total funds 2023 £</b>	<i>Total funds 2022 £</i>
Staff costs	<b>22,137</b>	71,234
Depreciation	<b>18</b>	858
Equipment leasing	<b>-</b>	2,982
Operating lease - office rent & service charges	<b>53,905</b>	29,064
Rates and water	<b>5,423</b>	1,638
Insurance	<b>(263)</b>	1,068
Marketing and advertising	<b>59,455</b>	115,238
Telephone	<b>1,884</b>	2,708
Postage and stationery	<b>6,076</b>	2,005
Computer and website support	<b>4,367</b>	21,402
Travel	<b>408</b>	1,099
Subscriptions	<b>1,029</b>	1,449
Sundries	<b>179</b>	760
Training	<b>-</b>	15
Legal and Professional fees	<b>648</b>	106,064
Conference expenses	<b>94,367</b>	37,288
Bank charges	<b>170</b>	616
Donation to CIO	<b>746,271</b>	-
	<b>996,074</b>	395,488

**8. Staff costs**

	<b>2023 £</b>	<i>2022 £</i>
Wages and salaries	<b>20,986</b>	67,958
Social security costs	<b>964</b>	2,398
Contribution to defined contribution pension schemes	<b>187</b>	877
	<b>22,137</b>	71,233

---

**ALAN MOREMENT MEMORIAL FUND**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2023**

---

**8. Staff costs (continued)**

The average number of persons employed by the Charity during the year was as follows:

	<b>2023</b>	<i>2022</i>
	<b>No.</b>	<i>No.</i>
Employees	<b>2</b>	<i>3</i>

No employee received remuneration amounting to more than £60,000 in either year.

**9. Trustees' remuneration and expenses**

During the year, no Trustees received any remuneration or other benefits (*2022 - £NIL*).

During the year ended 31 January 2023, no Trustee expenses have been incurred (*2022 - £NIL*).

**10. Stocks**

	<b>2023</b>	<i>2022</i>
	<b>£</b>	<i>£</i>
Finished goods and goods for resale	<b>-</b>	<i>7,122</i>

---

ALAN MOREMENT MEMORIAL FUND

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2023

---

11. Debtors

	2023 £	2022 £
<b>Due within one year</b>		
Other debtors	-	1,228
Prepayments and accrued income	-	10,916
	<u>-</u>	<u>12,144</u>
	<u>-</u>	<u>12,144</u>

12. Creditors: Amounts falling due within one year

	2023 £	2022 £
Trade creditors	-	123,276
Other creditors	-	1,370
Accruals and deferred income	-	1,800
	<u>-</u>	<u>126,446</u>
	<u>-</u>	<u>126,446</u>

---

**ALAN MOREMENT MEMORIAL FUND**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2023**

---

**13. Statement of funds**

**Statement of funds - current year**

	<b>Balance at 1 February 2022 £</b>	<b>Income £</b>	<b>Expenditure £</b>	<b>Balance at 31 January 2023 £</b>
<b>Unrestricted funds</b>				
General Funds - all funds	<b>502,965</b>	<b>251,128</b>	<b>(753,993)</b>	<b>100</b>
<b>Restricted funds</b>				
Restricted Research Funds	<b>21,120</b>	<b>-</b>	<b>(21,120)</b>	<b>-</b>
European Website Project	<b>42,828</b>	<b>-</b>	<b>(42,828)</b>	<b>-</b>
European Conference 2022	<b>59,790</b>	<b>131,639</b>	<b>(191,429)</b>	<b>-</b>
	<b>123,738</b>	<b>131,639</b>	<b>(255,377)</b>	<b>-</b>
<b>Total of funds</b>	<b>626,703</b>	<b>382,767</b>	<b>(1,009,370)</b>	<b>100</b>

Restricted research funds represent donations where the donor has requested that their donation be used for research purposes only. These donations are held within restricted funds until used in part or in whole to fund a cholangiocarcinoma research project which the charity has committed to supporting.

Restricted funds for the European website project represent donations where the donor has requested that their donation be used for this project only. These donations are held within restricted funds until used in part or in whole to fund the completion of the European website project.

Restricted funds for the European conference 2022 represent donations where the donor has requested that their donation be used for this conference only. These donations are held within restricted funds until used in part or in whole to fund the European conference 2022.

**ALAN MOREMENT MEMORIAL FUND**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2023**

**13. Statement of funds (continued)**

**Statement of funds - prior year**

	<i>Balance at 1 February 2021 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Balance at 31 January 2022 £</i>
<b>Unrestricted funds</b>				
General Funds - all funds	399,084	695,732	(591,851)	502,965
	<hr/>	<hr/>	<hr/>	<hr/>
	<i>Balance at 1 February 2021 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Balance at 31 January 2022 £</i>
<b>Restricted funds</b>				
Restricted Research Funds	21,120	-	-	21,120
European Website Project	-	80,618	(37,790)	42,828
European Conference 2022	-	60,000	(210)	59,790
	<hr/>	<hr/>	<hr/>	<hr/>
	21,120	140,618	(38,000)	123,738
	<hr/>	<hr/>	<hr/>	<hr/>
<b>Total of funds</b>	<b>420,204</b>	<b>836,350</b>	<b>(629,851)</b>	<b>626,703</b>
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

**14. Summary of funds**

**Summary of funds - current year**

	<b>Balance at 1 February 2022 £</b>	<b>Income £</b>	<b>Expenditure £</b>	<b>Balance at 31 January 2023 £</b>
General funds	502,965	251,128	(753,993)	100
Restricted funds	123,738	131,639	(255,377)	-
	<hr/>	<hr/>	<hr/>	<hr/>
	626,703	382,767	(1,009,370)	100
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

---

**ALAN MOREMENT MEMORIAL FUND**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2023**

---

**14. Summary of funds (continued)**

**Summary of funds - prior year**

	<i>Balance at 1 February 2021 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Balance at 31 January 2022 £</i>
General funds	399,084	695,732	(591,851)	502,965
Restricted funds	21,120	140,618	(38,000)	123,738
	<u>420,204</u>	<u>836,350</u>	<u>(629,851)</u>	<u>626,703</u>

**15. Analysis of net assets between funds**

**Analysis of net assets between funds - current year**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>
Current assets	100	<b>100</b>
<b>Total</b>	<u>100</u>	<u><b>100</b></u>

**Analysis of net assets between funds - prior year**

	<i>Restricted funds 2022 £</i>	<i>Unrestricted funds 2022 £</i>	<i>Total funds 2022 £</i>
Current assets	123,738	629,411	753,149
Creditors due within one year	-	(126,446)	(126,446)
<b>Total</b>	<u>123,738</u>	<u>502,965</u>	<u>626,703</u>

**16. Related party transactions**

The Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 January 2023 other than those documented in note 17.

---

**ALAN MOREMENT MEMORIAL FUND**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2023**

---

**17. Corporate charity**

The charity set up a corporate successor on 1st March 2022 called AMMF – The Cholangiocarcinoma Charity - 1198095 for the purpose of continuing the existing charity work.

At midnight on 31st May 2022 The Alan Morement Memorial Fund transferred its charitable undertaking to AMMF - The Cholangiocarcinoma Charity by way of a £746,271 donation.

As from 1st June 2022 all charity transactions have been recorded within the merged accounts of AMMF - The Cholangiocarcinoma Charity.

**THE ALAN MOREMENT MEMORIAL FUND**

England & Wales - Charity number 1091915

---

# Accounts

---

---

**AMMF**  
**THE ALAN MOREMENT MEMORIAL FUND**

---

**UNAUDITED**  
**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 JANUARY 2022**

Charity number: 1091915

---

**AMMF**  
**THE ALAN MOREMENT MEMORIAL FUND**

---

**UNAUDITED**

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 JANUARY 2022**

---

**ALAN MOREMENT MEMORIAL FUND**

---

**CONTENTS**

---

	Page
<b>Reference and Administrative Details of the Charity, its Trustees and Advisers</b>	1
<b>Trustees' Report</b>	2 - 7
<b>Trustees' Responsibilities Statement</b>	8
<b>Independent Examiner's Report</b>	9 - 11
<b>Statement of Financial Activities</b>	12
<b>Balance Sheet</b>	13
<b>Notes to the Financial Statements</b>	14 - 25

---

ALAN MOREMENT MEMORIAL FUND

---

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS  
FOR THE YEAR ENDED 31 JANUARY 2022

---

<b>Trustees</b>	N Corrigan, Chair G C Corrigan T P Morement H Corrigan
<b>Charity registered number</b>	1091915
<b>Principal office</b>	Enterprise House Bassingbourn Road Stansted Essex CM24 1QW
<b>Accountants</b>	Haslers Chartered Accountants Old Station Road Loughton Essex IG10 4PL

---

## ALAN MOREMENT MEMORIAL FUND

---

### TRUSTEES' REPORT FOR THE YEAR ENDED 31 JANUARY 2022

---

The trustees present their report with the financial statements of the charity for the year ended 31 January 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

#### OBJECTIVES AND ACTIVITIES

##### Objectives and aims

When AMMF was founded in the UK and registered with the Charity Commission in 2002, it was the world's first charity dedicated solely to cholangiocarcinoma (bile duct cancer). It remains the UK's and Europe's only dedicated cholangiocarcinoma (CCA) charity.

AMMF is wholly committed nationally and internationally to tackling this devastating cancer on all fronts and, ultimately, to help find a cure, through:

- **Support** - Providing information to individuals or groups to support a patient or loved one along their journey
- **Empowerment** – Empowering patients and their loved ones to advocate for themselves, seek better care, new treatment options and second opinions
- **Access** – Advocating for patients to ensure they have access to the latest treatment options and a minimum standard of care appropriate to them
- **Awareness** – Raising awareness of cholangiocarcinoma to support earlier diagnosis, fair and equal access to treatments, including new treatment approaches
- **Research** – Encouraging and supporting continued research into causes, diagnostics, and new treatment options for those with cholangiocarcinoma
- **Policy** – Ensuring health care policies reflect the needs of those with cholangiocarcinoma

Cholangiocarcinoma is under-represented and under-funded across all areas, including policy, services, and research. It is a poorly understood and under researched disease which is increasing in incidence not only in the UK but throughout the world. Lack of awareness and the difficulties of achieving clear and accurate diagnosis, mean that most are at an advanced stage and inoperable at time of diagnosis.

Surgery remains the only potentially curative treatment - there is palliative chemotherapy and there are a growing number of clinical trials, in particular investigating targeted therapies and immunotherapy - but a diagnosis of inoperable cholangiocarcinoma remains invariably fatal, and this is a situation that has not changed in decades. AMMF is committed to working to change this scenario and strongly believes international collaboration is the way forward.

Resolute in bringing about improvement for the cholangiocarcinoma patient, AMMF continues to work closely with patients and their carers, clinicians, healthcare professionals, researchers, and policy makers, as well as actively collaborating globally.

During the year 2021, despite the continuing limitations brought about by the ongoing COVID-19 pandemic, the charity continued its advocacy work, especially in helping cholangiocarcinoma patients navigate their way to continue essential treatments wherever possible.

##### AMMF's MISSION

A world improved for the cholangiocarcinoma patient by the sharing of knowledge across the healthcare and research communities and with the family of affected people across the globe.

---

## ALAN MOREMENT MEMORIAL FUND

---

### TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2022

---

#### **AMMF's VISION**

A world where people can live their lives free of cholangiocarcinoma (CCA) as a life-threatening disease.

#### **Raising Awareness**

##### **Cholangiocarcinoma Data Analysis Project**

Lack of robust data for cholangiocarcinoma has long been seen by AMMF as a major reason why there is so little awareness of this cancer, and so little progress. Robust data are essential to drive policy, to encourage research funding, to stimulate interest, and so much more.

Working towards rectifying this, Helen Morement, CEO of AMMF, along with Professor Shahid Khan, a hepatologist, and Professor Mireille Toledano, an epidemiologist, both of Imperial College London, prepared a cholangiocarcinoma data project proposal which was submitted to and accepted by the National Cancer Registration and Analysis Service (NCRAS) and PHE (Public Health England) and, in 2019, AMMF entered into a partnership with NCRAS and PHE, employed a data analyst specifically for this work, and the project began.

The pandemic has caused a number of delays, so the CCA data project is ongoing. After PHE completed the first part of the project, rather than directly employ another analyst, during the latter part of 2020 AMMF placed the project with the agency HDI (Health Data Insight/Public Health England). HDI have continued the work and liaise with PHE on AMMF's behalf. This project continued throughout 2021 and into 2022.

Dr Sophie Jose, Senior Analyst at HDI, presented some of the early findings at AMMF's conference in May 2021, one of which is the disturbing fact that 50% of those receiving a diagnosis of cholangiocarcinoma in England receive no treatment at all. Other key points the data project has uncovered include:

- Rates of CCA are continuing to increase year on year.
- Survival continues to be very poor (median survival still only 4 months).
- There is marked regional variation in incidence and mortality around the country, which has persisted and even worsened over time.
- Overall survival seems to be significantly lower in the most deprived.
- The most common route to diagnosis for cholangiocarcinoma remains the emergency route, which emphasises the poor rate of early diagnosis and the late presentation of this disease.

In March 2021, AMMF's CEO Helen Morement was able to refer to some of the findings from the first part of the project in an interview for the online Guardian, which resulted in an article, "A ticking time bomb? The rare liver cancer on the rise in younger people" which appeared as part of their Rare Diseases campaign:  
<https://www.healthawareness.co.uk/rare-diseases/a-ticking-time-bomb-the-rare-liver-cancer-on-the-rise-in-younger-people/>

It is hoped the CCA data project will reach completion ready for publication during 2022, and AMMF believes the final outcome will answer many of the questions there currently are relating to the epidemiological trends of cholangiocarcinoma, and will help in the charity's work towards better recognition for this cancer and an improved situation for all those diagnosed with it.

#### **AMMF's Virtual Cholangiocarcinoma Conference 2021**

In 2021, because of the ongoing uncertainties and travel limitations of the pandemic, the decision was taken to hold AMMF's annual cholangiocarcinoma conference as a virtual event for the first time. On 13–14 May 2021 AMMF brought together an expert faculty and speakers to deliver an online event which had a specific UK and European focus.

The conference was open for all with an interest in CCA, including specialists, scientists, researchers, patients and carers. A total of 620 delegates from six continents registered, and over the two days 26 presentations were delivered, plus 10 live Q&A sessions. Throughout both days, health care professionals were able to visit a virtual

---

## ALAN MOREMENT MEMORIAL FUND

---

### TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2022

---

poster hall to see and hear 17 poster presentations, and also visit the virtual exhibition hall to meet AMMF's sponsors, supporters and representatives of fellow CCA societies from around the world.

As well as presenters from across the UK and Europe giving updates on treatments and clinical trials, there were presentations giving international insights from China and Southeast Asia.

Scientific updates were delivered by researchers from six of the projects funded by AMMF and these, as well as the scientific updates on experimental modelling, shone a light on the efforts that are being made to understand the complexity of CCA and to develop new diagnostic tools and therapies which will hopefully lead to improved patient outcomes.

All the conference sessions were recorded and remain available to view via AMMF's website.

#### **AMMF's European Language Website**

AMMF is committed to supporting those with cholangiocarcinoma and, living in a multicultural, multilingual society, it was decided to provide translations of generic sections of AMMF's existing, main website to give all those with CCA the support they need and deserve through greater access to the information and resources AMMF provides.

Developed throughout 2021, at the start of 2022 AMMF was delighted to announce the launch of a companion website available in 8 European languages – Spanish, French, German, Italian, Polish, Portuguese, Danish, Finnish. [www.ammf-eu.org](http://www.ammf-eu.org)

#### **The Global Cholangiocarcinoma Alliance**

Building on the foundation of three successful annual World Cholangiocarcinoma Days, a venture which was initially an AMMF-instigated initiative, The Global Cholangiocarcinoma Alliance (GCA) was established at AMMF's international workshop held in London in 2018. This Alliance aims to provide a united voice through international collaboration, to seek further ways to drive awareness and education globally, and to address the current challenges in cholangiocarcinoma.

Since that time, and throughout 2021, AMMF continued to work with the agency Scientific Education Support (SES), acting as the not-for-profit partner as the work towards formalising a governance structure and the formation of an international steering committee was completed.

The International steering committee provided direction and content recommendations for all aspects of the Global Cholangiocarcinoma Alliance during 2021, and the agency SES partnered with them in a comprehensive portfolio of initiatives, including the annual World Cholangiocarcinoma Day and the development of a dedicated website, designed to provide the global cholangiocarcinoma community with a platform on which to build links and exchange knowledge in order to raise the global awareness of CCA and improve the education of both healthcare professionals and patients.

During 2021, because of the ongoing pandemic, all meetings of the GCA were held virtually. [globalccaalliance.com](http://globalccaalliance.com)

#### **AMMF Patient Advisory Roundtables – “Beyond the diagnosis – the impact of CCA”**

In order to discuss with patients in a structured way what the 'unseen' impact a diagnosis of CCA has on their lives, and to learn what areas of unmet needs there are which could help steer some of the charity's future work, AMMF held two patient advisory roundtables during the year, one in July and another in November. These resulted in several insightful findings, some of which have been used to produce information for patients on nutrition, and on molecular profiling. These resources are now available in hard copy and to download from AMMF's website.

#### **Public Benefit**

In forming the charity's objectives and planning the activities, the trustees have considered the Charity Commission's guidance in respect of public benefit.

---

## ALAN MOREMENT MEMORIAL FUND

---

### TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2022

---

#### ACHIEVEMENT AND PERFORMANCE

Although AMMF remains committed to supporting research into cholangiocarcinoma, because of the uncertainties surrounding income streams during the ongoing pandemic, the board decided not to open to new research funding applications during the year 2021.

Many existing awardees asked for no cost extensions because labs had been closed during the pandemic, resulting in delays to finalizing research work.

During 2021 the following payments were made re existing awards:

**University of Oxford** - £8,389.77 (4th instalment) was paid in November 2021 in respect of an award of £90,000 agreed in May 2018 to be given in 4 instalments to fund Dr Shijie Cai's work re an integrated proteomic and metabolomics approach to investigate the role of ubiquitin-specific protease 22 and its responsive pathways in cholangiocarcinoma.

**University of Nottingham** – £12,508.04 was paid in August 2021, in respect of the 2nd and final instalment of an award of £28,750.29 agreed in June 2020, to be given in two instalments to fund consumables and technical support for Dr Isioma Egbuniwe's work on "Interleukin 17 (IL-17) in Tumour Lymphangiogenesis in Cholangiocarcinoma".

**University of Leeds** – a total of £18,931.83 was paid during the year 2021 - 2022 against invoiced actual consumable spend (February 2021: £1,132.83, April 2021: £7,698.83, July 2021: £3,933.04, November 2021: £4,742.30, January 2022: £1,424.03) in respect of an award of £45,000 which was agreed in July 2018 to be given over three years, to fund consumables required in the work of Dr Stephen Griffin on virus-driven intrahepatic cholangiocarcinoma.

**Donostia University Hospital, Spain** - £10,964.95 (2nd instalment) was paid in Euros in September 2021 in respect of an award of £32,048.00 agreed in 2019 to be given in 3 instalments to fund Dr Jesus Bañales's work on the role of the transcription factor KLF5 in the etiopathogenesis of cholangiocarcinoma, a new diagnostic, prognostic and therapeutic strategy.

#### AMMF's External Activities

The charity is recognized widely, nationally and internationally, amongst both the general public and within medical circles, for its work in the field of cholangiocarcinoma, and is frequently invited to become part of study groups and advisory boards, for example, the working group for Liver Transplantation for Cholangiocarcinoma, and the executive committee of Cholangiocarcinoma-UK.

AMMF is also a member of the European Network for the Study of Cholangiocarcinoma (ENS-CCA), an association of research groups from across Europe and beyond, actively working on basic, translational, and clinical research into cholangiocarcinoma, and the charity's CEO is chair of the ENS-CCA Patient Advocacy Committee.

AMMF continues to be an active member of Cancer52, the alliance of rare and less common cancer organisations, which provides "the common voice for less common cancers". AMMF's CEO, Helen Morement was appointed a board director of Cancer52 in 2014, and has continued in this role since then, during 2021 attending board meetings and general meetings virtually. Through this membership, the charity is enabled to have a presence and a voice within every national cancer initiative. AMMF's trustees see this role as providing an opportunity to work more closely with this increasingly influential organisation, and in identifying priority challenges and opportunities for all those in the rare and less common cancers community.

Late in 2020, AMMF was requested by NICE (National Institute for Health and Care Excellence) to put forward representatives to provide an appraisal of a targeted agent for the treatment of those with cholangiocarcinoma. AMMF's CEO provided a written statement and in April 2021, along with a CCA patient, attended a virtual NICE appraisal committee meeting where both gave verbal statements in support of this treatment. The treatment, pemigatinib, has now received NICE approval and is the first targeted therapy for those with cholangiocarcinoma

---

## ALAN MOREMENT MEMORIAL FUND

---

### TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 JANUARY 2022

---

with an FGFR2 fusion. Importantly, this decision opened the door to molecular profiling for all diagnosed with this challenging cancer.

With all overseas and UK conferences and face to face meetings cancelled, these were replaced wherever possible by virtual events. During the year, AMMF attended and presented at a number of these virtual events, including DIA Europe, the UK Oncology Forum conference and ESMO World Congress.

#### **Information for those who need it, and providing patient information during the pandemic:**

As the pandemic continued during 2021, AMMF's CEO attended weekly virtual NHS cancer charity briefing meetings in order to provide the clearest possible information to those who approached the charity for help. AMMF's Medical and Clinical Advisors were also contacted on a regular basis, to gain an overview of the difficulties that they were experiencing in being able to care for their CCA patients, and for advice on how best to handle the patient queries the charity was receiving.

The Patient Support area of AMMF's website included a section with COVID-19 advice for CCA patients, with links to appropriate NHS and Government information, and this was updated on a regular basis. Helpful information was also disseminated across AMMF's social media channels whenever possible.

The general areas of AMMF's website continued to be updated regularly, including the area for COVID-19 advice for CCA patients. The website aims to provide information on all aspects of cholangiocarcinoma, including treatments and specialists, the advances being made and, importantly, there is a comprehensive list of the clinical trials that are available and recruiting in the UK, which is proving a valuable resource to medics and patients. [www.ammf.org.uk](http://www.ammf.org.uk)

The charity's active social media platforms kept supporters up to date with information of importance and relevance to them throughout the year. AMMF's Facebook page now has over 5,500 followers, and the following on Twitter, Instagram and LinkedIn continues to grow.

In answer to patients' requests, AMMF opened two private, member only, support groups on Facebook - Cholangiocarcinoma Support – UK and Europe, and a group for those bereaved by cholangiocarcinoma. These have been well received and are proving an invaluable resource for patients to share information, and for them to help and support each other.

The requirement from individual patients and family members for specific information regarding specialist consultants and treatments continues to increase. With the wider awareness of the charity, increasing incidence and growing recognition of cholangiocarcinoma, it is anticipated this area of work will continue to grow.

#### **In summary**

AMMF continued working remotely throughout 2021, with team meetings take place daily via Zoom, and each member of staff continuing to work their normal hours.

The pandemic has caused unforeseen difficulties but, despite the problems, the charity has continued its work steadfastly throughout the year, and expanded its reach and influence nationally and internationally.

AMMF is the UK's only cholangiocarcinoma charity and, although by its nature will remain a niche charity, is now firmly established in the UK, Europe and beyond. As we enter 2022, we look forward with some caution because of the ongoing problems of the pandemic but, with the help of our loyal fundraisers and supporters who have supported us throughout the year, AMMF remains fully committed to working towards a far better future for all those diagnosed with cholangiocarcinoma.

#### **Financial review**

##### **Financial review and reserves policy**

The charity has continued to strengthen its financial position during the year.

The charity ensures that sufficient reserves are retained in an appropriate form to fund its current obligations.

---

**ALAN MOREMENT MEMORIAL FUND**

---

**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 31 JANUARY 2022**

---

Where specific research projects have been secured, the trustees designate sufficient unrestricted reserves to cover the expected future grants payable over the term of the research project.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charity is controlled by its governing document, a deed of trust, and constitutes an unincorporated charity.

Approved by order of the members of the board of Trustees on 24 November 2022 and signed on their behalf by:



**N Corrigan**  
(Chair of Trustees)

---

**ALAN MOREMENT MEMORIAL FUND**

---

**STATEMENT OF TRUSTEES' RESPONSIBILITIES  
FOR THE YEAR ENDED 31 JANUARY 2022**

---

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on 24 November 2022 and signed on its behalf by:



**N Corrigan**  
(Chair of Trustees)

---

**ALAN MOREMENT MEMORIAL FUND**

---

**INDEPENDENT EXAMINER'S REPORT  
FOR THE YEAR ENDED 31 JANUARY 2022**

---

**Independent Examiner's Report to the Trustees of Alan Morement Memorial Fund ('the Charity')**

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 January 2022.

**Responsibilities and Basis of Report**

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

---

**ALAN MOREMENT MEMORIAL FUND**

---

**INDEPENDENT EXAMINER'S REPORT (CONTINUED)  
FOR THE YEAR ENDED 31 JANUARY 2022**

---

**Independent Examiner's Statement**

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ACCA, which is one of the listed bodies.

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

---

ALAN MOREMENT MEMORIAL FUND

---

INDEPENDENT EXAMINER'S REPORT (CONTINUED)  
FOR THE YEAR ENDED 31 JANUARY 2022

---

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed: 

Dated: 24 November 2022

P Thain

**Haslers**

Chartered Accountants  
Old Station Road  
Loughton  
Essex  
IG10 4PL

---

**ALAN MOREMENT MEMORIAL FUND**

---

**STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 JANUARY 2022**

---

	Note	Restricted funds 2022 £	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
<b>Income from:</b>					
Donations and legacies	3	140,618	681,031	821,649	439,405
Charitable activities	4	-	-	-	10,000
Other trading activities	5	-	14,055	14,055	5,108
Investments	6	-	646	646	1,146
<b>Total income</b>		<b>140,618</b>	<b>695,732</b>	<b>836,350</b>	<b>455,659</b>
<b>Expenditure on:</b>					
Raising funds		-	2,276	2,276	7,486
Charitable activities	7	38,000	589,575	627,575	391,466
<b>Total expenditure</b>		<b>38,000</b>	<b>591,851</b>	<b>629,851</b>	<b>398,952</b>
<b>Net movement in funds</b>		<b>102,618</b>	<b>103,881</b>	<b>206,499</b>	<b>56,707</b>
<b>Reconciliation of funds:</b>					
Total funds brought forward		21,120	399,084	420,204	363,497
Net movement in funds		102,618	103,881	206,499	56,707
<b>Total funds carried forward</b>		<b>123,738</b>	<b>502,965</b>	<b>626,703</b>	<b>420,204</b>

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 14 to 25 form part of these financial statements.

---

**ALAN MOREMENT MEMORIAL FUND**

---

**BALANCE SHEET  
AS AT 31 JANUARY 2022**

---

	Note	2022 £	2021 £
<b>Fixed assets</b>			
Tangible assets	11	-	857
		-	857
<b>Current assets</b>			
Stocks	12	7,122	5,355
Debtors	13	12,144	10,816
Cash at bank and in hand		733,883	407,936
		753,149	424,107
Creditors: amounts falling due within one year	14	(126,446)	(4,760)
<b>Net current assets</b>		<b>626,703</b>	<b>419,347</b>
<b>Total assets less current liabilities</b>		<b>626,703</b>	<b>420,204</b>
<b>Total net assets</b>		<b>626,703</b>	<b>420,204</b>
<b>Charity funds</b>			
Restricted funds	15	123,738	21,120
Unrestricted funds	15	502,965	399,084
<b>Total funds</b>		<b>626,703</b>	<b>420,204</b>

The financial statements were approved and authorised for issue by the Trustees on 24 November 2022 and signed on their behalf by:



**N Corrigan**  
(Chair of Trustees)

The notes on pages 14 to 25 form part of these financial statements.

---

## ALAN MOREMENT MEMORIAL FUND

---

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2022

---

#### 1. General information

Alan Morement Memorial Fund is an unincorporated charity, domiciled in England and Wales, registration number 1091915. The registered office is Haslers, Old Station Road, Loughton, Essex, IG10 4PL and the principal place of business is throughout the United Kingdom. The principal aim of the charity is to raise awareness of cholangiocarcinoma (bile duct cancer), supply information to those who need it, and to raise funds to support specialised research teams in their work into the causes, methods of earlier diagnosis and treatments of this disease.

#### 2. Accounting policies

##### 2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Alan Morement Memorial Fund meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

##### 2.2 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

##### 2.3 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

---

**ALAN MOREMENT MEMORIAL FUND**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2022**

---

**2. Accounting policies (continued)**

**2.3 Expenditure (continued)**

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

**2.4 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

**2.5 Tangible fixed assets and depreciation**

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Computer equipment	-	33%
--------------------	---	-----

**2.6 Stocks**

Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.

**2.7 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**2.8 Cash at bank and in hand**

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

---

ALAN MOREMENT MEMORIAL FUND

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2022

---

2. Accounting policies (continued)

2.9 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of Financial Activities as a finance cost.

2.10 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Income from donations and legacies

	<b>Restricted funds 2022 £</b>	<b>Unrestricted funds 2022 £</b>	<b>Total funds 2022 £</b>	<i>Total funds 2021 £</i>
Donations	140,618	681,031	<b>821,649</b>	439,405
<i>Total 2021</i>	-	439,405	439,405	

---

ALAN MOREMENT MEMORIAL FUND

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2022

---

4. Income from charitable activities

	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Discretionary grant award	-	-	10,000
	<hr/>	<hr/>	<hr/>
<i>Total 2021</i>	<hr/> 10,000 <hr/>	<hr/> 10,000 <hr/>	

5. Income from other trading activities

Income from non charitable trading activities

	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Shop income	14,055	14,055	5,108
	<hr/>	<hr/>	<hr/>

6. Investment income

	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Deposit account interest	646	646	1,146
	<hr/>	<hr/>	<hr/>
<i>Total 2021</i>	<hr/> 1,146 <hr/>	<hr/> 1,146 <hr/>	

---

**ALAN MOREMENT MEMORIAL FUND**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2022**

---

**7. Analysis of expenditure on charitable activities**

**Summary by fund type**

	<b>Restricted funds 2022 £</b>	<b>Unrestricted funds 2022 £</b>	<b>Total 2022 £</b>	<i>Total 2021 £</i>
Costs	38,000	589,575	<b>627,575</b>	391,466
	<u>38,000</u>	<u>589,575</u>	<u><b>627,575</b></u>	<u>391,466</u>

**8. Analysis of expenditure by activities**

	<b>Activities undertaken directly 2022 £</b>	<b>Support costs 2022 £</b>	<b>Total funds 2022 £</b>	<i>Total funds 2021 £</i>
Costs	232,087	395,488	<b>627,575</b>	391,466
	<u>232,087</u>	<u>395,488</u>	<u><b>627,575</b></u>	<u>391,466</u>
<i>Total 2021</i>	<u>260,035</u>	<u>131,431</u>	<u>391,466</u>	

**Analysis of direct costs**

	<b>Total funds 2022 £</b>	<i>Total funds 2021 £</i>
Grants to institutions	<b>194,087</b>	260,035
European Website costs	<b>37,790</b>	-
European Conference 2022 costs	<b>210</b>	-
	<u><b>232,087</b></u>	<u>260,035</u>

---

**ALAN MOREMENT MEMORIAL FUND**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2022**

---

**8. Analysis of expenditure by activities (continued)**

**Analysis of support costs**

	<b>Total funds 2022</b>	<i>Total funds 2021</i>
	£	£
Staff costs	71,234	66,436
Depreciation	858	1,146
Equipment leasing	2,982	2,982
Operating lease - office rent & service charges	29,064	26,472
Rates and water	1,638	1,634
Insurance	1,068	529
Marketing and advertising	115,238	5,284
Telephone	2,708	3,162
Postage and stationery	2,005	3,984
Computer and website support	21,402	10,249
Travel	1,099	1,870
Subscriptions	1,449	1,230
Sundries	760	23
Training	15	50
Legal and Professional fees	106,064	2,934
Conference expenses	37,288	2,874
Bank charges	616	572
	<b>395,488</b>	<i>131,431</i>

**9. Staff costs**

	<b>2022</b>	<i>2021</i>
	£	£
Wages and salaries	67,958	64,546
Social security costs	2,398	1,282
Contribution to defined contribution pension schemes	877	608
	<b>71,233</b>	<i>66,436</i>

---

ALAN MOREMENT MEMORIAL FUND

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2022

---

9. Staff costs (continued)

The average number of persons employed by the Charity during the year was as follows:

	<b>2022</b>	<i>2021</i>
	<b>No.</b>	<i>No.</i>
Employees	<b>3</b>	<i>3</i>

No employee received remuneration amounting to more than £60,000 in either year.

10. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (*2021 - £NIL*).

During the year ended 31 January 2022, no Trustee expenses have been incurred (*2021 - £NIL*).

---

ALAN MOREMENT MEMORIAL FUND

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2022

---

11. Tangible fixed assets

	Computer equipment £
<b>Cost or valuation</b>	
At 1 February 2021	10,305
At 31 January 2022	<u>10,305</u>
<b>Depreciation</b>	
At 1 February 2021	9,448
Charge for the year	857
At 31 January 2022	<u>10,305</u>
<b>Net book value</b>	
At 31 January 2022	-
At 31 January 2021	<u>857</u>

12. Stocks

	2022 £	2021 £
Finished goods and goods for resale	<u>7,122</u>	<u>5,355</u>

---

ALAN MOREMENT MEMORIAL FUND

---

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2022

---

13. Debtors

	2022 £	2021 £
<b>Due within one year</b>		
Other debtors	1,228	-
Prepayments and accrued income	10,916	10,816
	<u>12,144</u>	<u>10,816</u>

14. Creditors: Amounts falling due within one year

	2022 £	2021 £
Trade creditors	123,276	-
Other creditors	1,370	2,164
Accruals and deferred income	1,800	2,596
	<u>126,446</u>	<u>4,760</u>

---

**ALAN MOREMENT MEMORIAL FUND**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2022**

---

**15. Statement of funds**

**Statement of funds - current year**

	Balance at 1 February 2021 £	Income £	Expenditure £	Balance at 31 January 2022 £
<b>Unrestricted funds</b>				
General Funds - all funds	399,084	695,732	(591,851)	502,965
<b>Restricted funds</b>				
Restricted Research Funds	21,120	-	-	21,120
European Website Project	-	80,618	(37,790)	42,828
European Conference 2022	-	60,000	(210)	59,790
	<u>21,120</u>	<u>140,618</u>	<u>(38,000)</u>	<u>123,738</u>
<b>Total of funds</b>	<b><u>420,204</u></b>	<b><u>836,350</u></b>	<b><u>(629,851)</u></b>	<b><u>626,703</u></b>

Restricted research funds represent donations where the donor has requested that their donation be used for research purposes only. These donations are held within restricted funds until used in part or in whole to fund a cholangiocarcinoma research project which the charity has committed to supporting.

Restricted funds for the European website project represent donations where the donor has requested that their donation be used for this project only. These donations are held within restricted funds until used in part or in whole to fund the completion of the European website project.

Restricted funds for the European conference 2022 represent donations where the donor has requested that their donation be used for this conference only. These donations are held within restricted funds until used in part or in whole to fund the European conference 2022.

---

**ALAN MOREMENT MEMORIAL FUND**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2022**

---

**15. Statement of funds (continued)**

**Statement of funds - prior year**

	<i>Balance at 1 February 2020 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Balance at 31 January 2021 £</i>
<b>Unrestricted funds</b>				
General Funds - all funds	360,065	437,971	(398,952)	399,084
	<hr/>	<hr/>	<hr/>	<hr/>
	<i>Balance at 1 February 2020 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Balance at 31 January 2021 £</i>
<b>Restricted funds</b>				
Restricted Research Funds	3,432	17,688	-	21,120
	<hr/>	<hr/>	<hr/>	<hr/>
<b>Total of funds</b>	<b>363,497</b>	<b>455,659</b>	<b>(398,952)</b>	<b>420,204</b>
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

**16. Summary of funds**

**Summary of funds - current year**

	<b>Balance at 1 February 2021 £</b>	<b>Income £</b>	<b>Expenditure £</b>	<b>Balance at 31 January 2022 £</b>
General funds	399,084	695,732	(591,851)	502,965
Restricted funds	21,120	140,618	(38,000)	123,738
	<hr/>	<hr/>	<hr/>	<hr/>
	<b>420,204</b>	<b>836,350</b>	<b>(629,851)</b>	<b>626,703</b>
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

---

**ALAN MOREMENT MEMORIAL FUND**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2022**

---

**16. Summary of funds (continued)**

**Summary of funds - prior year**

	<i>Balance at 1 February 2020</i>	<i>Income</i>	<i>Expenditure</i>	<i>Balance at 31 January 2021</i>
	£	£	£	£
General funds	360,065	437,971	(398,952)	399,084
Restricted funds	3,432	17,688	-	21,120
	<u>363,497</u>	<u>455,659</u>	<u>(398,952)</u>	<u>420,204</u>
	<u>363,497</u>	<u>455,659</u>	<u>(398,952)</u>	<u>420,204</u>

**17. Analysis of net assets between funds**

**Analysis of net assets between funds - current year**

	<b>Restricted funds 2022</b>	<b>Unrestricted funds 2022</b>	<b>Total funds 2022</b>
	£	£	£
Current assets	123,738	629,411	<b>753,149</b>
Creditors due within one year	-	(126,446)	<b>(126,446)</b>
<b>Total</b>	<u>123,738</u>	<u>502,965</u>	<u><b>626,703</b></u>
	<u>123,738</u>	<u>502,965</u>	<u><b>626,703</b></u>

**18. Related party transactions**

The Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 January 2022.

**THE ALAN MOREMENT MEMORIAL FUND**

England & Wales - Charity number 1091915

---

# Accounts

---

**REGISTERED CHARITY NUMBER: 1091915**

**REPORT OF THE TRUSTEES AND  
FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2021  
FOR  
AMMF  
(THE ALAN MOREMENT MEMORIAL FUND)**

Haslers  
Chartered Accountants  
Old Station Road  
Loughton  
Essex  
IG10 4PL

**AMMF  
(THE ALAN MOREMENT MEMORIAL FUND)**

**CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2021**

	<b>Page</b>
<b>Reference and Administrative Details</b>	1
<b>Report of the Trustees</b>	2 to 8
<b>Independent Examiner's Report</b>	9
<b>Statement of Financial Activities</b>	10
<b>Balance Sheet</b>	11
<b>Notes to the Financial Statements</b>	12 to 18
<b>Detailed Statement of Financial Activities</b>	19 to 20

**AMMF  
(THE ALAN MOREMENT MEMORIAL FUND)**

**REFERENCE AND ADMINISTRATIVE DETAILS  
FOR THE YEAR ENDED 31 JANUARY 2021**

<b>TRUSTEES</b>	Mr T P Morement Mr N Corrigan Chairman Mr H Corrigan Mrs G C Meares Corrigan
<b>PRINCIPAL ADDRESS</b>	Enterprise House Bassingbourn Road Stansted Essex CM24 1QW
<b>REGISTERED CHARITY NUMBER</b>	1091915
<b>INDEPENDENT EXAMINER</b>	Haslers Chartered Accountants Old Station Road Loughton Essex IG10 4PL

**AMMF**  
**(THE ALAN MOREMENT MEMORIAL FUND)**

**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31 JANUARY 2021**

The trustees present their report with the financial statements of the charity for the year ended 31 January 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

**OBJECTIVES AND ACTIVITIES**

**Objectives and aims**

When AMMF was founded in the UK and registered with the Charity Commission in 2002, it was the world's first charity dedicated solely to cholangiocarcinoma (bile duct cancer). It remains the UK's and Europe's only dedicated cholangiocarcinoma (CCA) charity.

AMMF is wholly committed nationally and internationally to tackling this devastating cancer on all fronts and, ultimately, to help find a cure, through:

- **Support** - Providing information to individuals or groups to support a patient or loved one along their journey
- **Empowerment** - Empowering patients and their loved ones to advocate for themselves, seek better care, new treatment options and second opinions
- **Access** - Advocating for patients to ensure they have access to the latest treatment options and a minimum standard of care appropriate to them
- **Awareness** - Raising awareness of cholangiocarcinoma to support earlier diagnosis, fair and equal access to treatments, including new treatment approaches
- **Research** - Encouraging and supporting continued research into causes, diagnostics, and new treatment options for those with cholangiocarcinoma
- **Policy** - Ensuring health care policies reflect the needs of those with cholangiocarcinoma

Cholangiocarcinoma is under-represented and under-funded across all areas, including policy, services, and research. It is a poorly understood and under researched disease which is increasing in incidence not only in the UK but throughout the world. Lack of awareness and the difficulties of achieving clear and accurate diagnosis, mean that most are at an advanced stage and inoperable at time of diagnosis.

Surgery remains the only potentially curative treatment - there is palliative chemotherapy and there are some trials - but a diagnosis of inoperable cholangiocarcinoma is invariably fatal, and this is a situation that has not changed in decades. AMMF is committed to working to change this scenario and strongly believes international collaboration is the way forward.

Resolute in bringing about improvement for the cholangiocarcinoma patient, AMMF continues to work closely with patients and their carers, clinicians, healthcare professionals, researchers, and policy makers, as well as actively collaborating globally.

During the year 2020, despite the limitations brought about by the COVID-19 pandemic, the charity continued its advocacy work, especially in helping cholangiocarcinoma patients navigate their way to continue essential treatments wherever possible.

**AMMF's MISSION**

A world improved for the cholangiocarcinoma patient by the sharing of knowledge across the healthcare and research communities and with the family of affected people across the globe.

**AMMF**  
**(THE ALAN MOREMENT MEMORIAL FUND)**

**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31 JANUARY 2021**

## **Raising Awareness**

### **The Global Cholangiocarcinoma Alliance**

Building on the foundation of three successful annual World Cholangiocarcinoma Days, an AMMF-instigated initiative, The Global Cholangiocarcinoma Alliance (GCA) was established at AMMF's international workshop held in London in 2018. This venture aims to provide a united voice through international collaboration, to seek further ways to drive awareness and education globally, and to address the current challenges in cholangiocarcinoma.

Since that time, and throughout 2020, AMMF continued to work with the agency Scientific Education Support (SES), acting as the not-for-profit partner as the work towards formalising a governance structure and the formation of an international steering committee was completed.

The newly formed steering committee provided direction and content recommendations for all aspects of the Global Cholangiocarcinoma Alliance during 2020, and the agency SES partnered with them in building a comprehensive portfolio of initiatives, designed to provide the global cholangiocarcinoma community with a platform on which to build links and exchange knowledge in order to raise the global awareness of CCA and improve the education of both healthcare professionals and patients. The projects will begin in 2021, and continue throughout the year, with SES ensuring they are delivered in accordance with agreed timelines.

Led by SES, World Cholangiocarcinoma Day 2020 was held on 12 February, with a social media focused campaign themed on sharing knowledge through global collaboration. The day was well-supported globally across social media, substantially raising the profile of the Global CCA Alliance. And at the end of 2020, plans were well underway for the 2021 World CCA Day.

Due to the COVID-19 pandemic, touchpoint GCA meetings planned to be held at major conferences throughout the year had to be cancelled, but where possible these were rescheduled to be held virtually. This enabled the work of the Alliance to continue.

## **OBJECTIVES AND ACTIVITIES**

### **Raising Awareness**

#### **AMMF's Cholangiocarcinoma Conference 2020**

Planning for AMMF's annual Cholangiocarcinoma Conference in May 2020 was well underway when the first compulsory lockdown of the COVID-19 pandemic began and, as the severity of the pandemic became clear, this event had to be postponed.

Later in the year AMMF held a smaller virtual event for patients and carers, to share with them some of the information they had missed from AMMF's main conference, but the charity was not able to organise main part of the conference as a virtual event during 2020.

**AMMF**  
**(THE ALAN MOREMENT MEMORIAL FUND)**

**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31 JANUARY 2021**

**Patient information day, October 2020**

AMMF's virtual Cholangiocarcinoma (CCA) Information Day, especially for patients and carers, took place on Thursday, 29 October 2020.

This was attended not only by patients and their loved ones, but also by clinical nurse specialists who wanted to learn more about cholangiocarcinoma, and by industry members, whose companies are working hard to develop drugs and improved treatments for those with CCA.

The day's agenda covered three important topics - an overview of cholangiocarcinoma, an update on treatments and trials, and a discussion on nutrition and diet for those with cholangiocarcinoma - and we were very fortunate to have with us expert speakers - Professor Shahid A Khan, Professor Juan Valle, and Ms Glenda O'Connor - each of whom are dedicated to helping improve the situation for all those now and in the future, with cholangiocarcinoma.

**Cholangiocarcinoma Data Analysis Project**

Lack of robust data for cholangiocarcinoma has long been seen by AMMF as a major reason why there is so little awareness of this cancer, and so little progress. Robust data are essential to drive policy, to encourage research funding, to stimulate interest, and so much more.

Working towards rectifying this, Helen Morement, CEO of AMMF, along with Professor Shahid A Khan, a hepatologist, and Professor Mireille Toledano, an epidemiologist, both of Imperial College London, prepared a cholangiocarcinoma data project proposal which was submitted to and accepted by the National Cancer Registration and Analysis Service (NCRAS) and PHE (Public Health England).

In 2019, AMMF entered into a partnership with NCRAS and PHE, employing a data analyst to be embedded with NCRAS to work on the first part of the project to show the incidence and mortality, and survival, including age/gender breakdown. A poster, showing early results of this work, had been presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer in Barcelona in the summer of 2019.

When AMMF's analyst left in early 2020, the first part of the project was substantially completed, and it had been hoped that this work, "Incidence, mortality and survival for people diagnosed in England with Cholangiocarcinoma between 2001-2017", would be ready for publication during 2020. However, the COVID-19 pandemic and the lockdowns delayed this, and we are now looking at publication towards the end of 2021.

The second part of the project, "Routes to diagnosis and treatment of cholangiocarcinoma in England from 2006 to 2017: Are there any inequalities?", was developed to investigate treatments received, regional variation, and more. This was submitted to and approved by NCRAS/PHE and AMMF then commissioned the organisation HDI (Health Data Insight) to carry out this work.

A poster highlighting further outcomes of the data project and entitled, "Cholangiocarcinoma in England - a national study examining changes in incidence, diagnostic routes and overall survival", was accepted for presentation at the EASL (European Association for the Study of the Liver) international Congress in London in November 2020.

It is hoped both parts of the project will reach completion ready for publication during 2021, and AMMF believes the final outcome of the CCA data project will answer many of the questions there currently are relating to the epidemiological trends of cholangiocarcinoma and will help in the charity's work towards better recognition for this cancer and an improved situation for all those diagnosed with it.

**AMMF**  
**(THE ALAN MOREMENT MEMORIAL FUND)**

**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31 JANUARY 2021**

**OBJECTIVES AND ACTIVITIES**

**Public benefit**

In forming the charity's objectives and planning the activities, the trustees have considered the Charity Commission's guidance in respect of public benefit.

**ACHIEVEMENT AND PERFORMANCE**

**Supporting Research**

AMMF remains committed to supporting research into cholangiocarcinoma.

**During the year 2020 new grant awards were agreed as follows:**

**University of Nottingham** - £28,750.29 was awarded in June 2020, to be given in two instalments, to fund consumables and technical support for Dr Isioma Egbuniwe's work on "Interleukin 17 (IL-17) in Tumour Lymphangiogenesis in Cholangiocarcinoma".

**University of Liverpool** - £25,000 awarded in June 2020, to be given in one instalment, to fund the work of Mr Marc Quinn, "Interrogating tumour-mediated immunosuppression in perihilar cholangiocarcinoma".

**During 2020 the following payments were made re new and existing awards:**

**University of Edinburgh** - £34,325 was paid in July 2020 in respect of the 2nd instalment of a grant of £102,515 awarded in September 2017 to fund a 3-year PhD scholarship in Dr Luke Boulter's lab, working on the project, "Understanding the role of seed cells and epithelial co-option in cholangiocarcinoma".

**University of Oxford** - £24,255.89 (3rd instalment) was paid in December 2020 in respect of an award of £90,000 agreed in May 2018 to be given over three years to fund Dr Shijie Cai's work re an integrated proteomic and metabolomics approach to investigate the role of ubiquitin-specific protease 22 and its responsive pathways in cholangiocarcinoma.

**University of Nottingham** - £19,262 was paid in one instalment in December 2020 in respect of an award of this amount agreed to fund one year of Dr Sheela Jayaraman's work on new strategies for the inhibition of cholangiocarcinoma tumour growth.

*Note: This award was originally made for Dr Jayaraman's work at the University of Birmingham, but she requested that it be moved with her to the University of Nottingham when she accepted a post there in October 2020. The research work remained the same, so AMMF's board of trustees agreed to this 05.10.2020.*

**University of Nottingham** - £16,169.00 was paid in December 2020, in respect of the first instalment of an award of £28,750.29 agreed in June 2020, to be given in two instalments, to fund consumables and technical support for Dr Isioma Egbuniwe's work on "Interleukin 17 (IL-17) in Tumour Lymphangiogenesis in Cholangiocarcinoma".

**University of Leeds** - a total of £12,470.58 was paid during the year against invoiced actual consumable spend (January 2020: £2,937.88, March 2020: £8,399.87, January 2021: £1,132.83) in respect of an award of £45,000 which was agreed in July 2018 to be given over three years, to fund consumables required in the work of Dr Stephen Griffin on virus-driven intrahepatic cholangiocarcinoma.

**AMMF**  
**(THE ALAN MOREMENT MEMORIAL FUND)**

**REPORT OF THE TRUSTEES**  
**FOR THE YEAR ENDED 31 JANUARY 2021**

**ACHIEVEMENT AND PERFORMANCE**

**AMMF's External Activities**

The charity is recognized widely, nationally and internationally, both amongst the general public and within medical circles, for its work in the field of cholangiocarcinoma.

As a member of the NCRI's (National Cancer Research Institute) Upper Gastrointestinal Hepatobiliary clinical trials group, and the IBTCC (International Biliary Tract Cancers Collaborators) group AMMF has made valuable contacts with those at the forefront of cholangiocarcinoma research and treatments throughout the UK and internationally.

**COVID-19**

During January and February 2020, it became apparent that there was a health crisis developing. The incredibly infectious and dangerous COVID-19 virus was building in intensity. At AMMF, external visitors were cancelled, as was attendance at external meetings. During those weeks, all staff were instructed to ensure that their AMMF-supplied computer and other equipment they already had in place for occasional working from home, was working well should we need to resort to remote working for a period of time, and contingency plans were put in place to ensure secure sharing of digital files during any such remote working.

With heightening concerns over the advance of the virus, on 18 March AMMF's board of trustees instructed AMMF's CEO and staff to begin working remotely until further notice, and on 23rd March 2020, Prime Minister, Boris Johnson, instigated the first nationwide full lockdown.

Working remotely continued throughout the year, with team meetings take place daily via Zoom, and each member of staff continuing to work their normal hours.

All overseas and UK conferences and face to face meetings were cancelled, replaced where possible by virtual events. During the year, AMMF attended and presented at a number of these virtual events, including the UK Oncology Forum conference, ESMO World Congress (virtual) with Helen Morement, AMMF's CEO, speaking at and co-chairing the Incyte symposium, and she was also invited to become part of Incyte's CCA Multi-Disciplinary Team Educational Campaign Advisory Board.

During the year, the charity was approached by NICE to put forward a submission for the approval of a new targeted therapy for cholangiocarcinoma, and the CEO was invited to sit on a US FDA (Food and Drug Administration) committee exploring improved eligibility rules for clinical trials.

AMMF is a member of the European Network for the Study of Cholangiocarcinoma (ENS-CCA), an association of research groups from twelve European countries actively working on basic, translational, and clinical research into cholangiocarcinoma, and the charity's CEO is chair of the ENS-CCA Patient Advocacy Committee.

AMMF continues to be an active member of Cancer52, the alliance of rare and less common cancer organisations, which provides "the common voice for less common cancers". AMMF's CEO, Helen Morement was appointed a board director of Cancer52 in 2014, and has continued in this role since then, during 2020 attending board meetings and general meetings virtually. Through this membership, the charity is enabled to have a presence and a voice within every national cancer initiative. AMMF's trustees see this role as providing an opportunity to work more closely with this influential organisation, and in identifying priority challenges and opportunities for all those in the rare and less common cancers community.

**AMMF  
(THE ALAN MOREMENT MEMORIAL FUND)**

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 JANUARY 2021**

**ACHIEVEMENT AND PERFORMANCE**

**Information for those who need it, and providing patient information during the pandemic:**

As the pandemic progressed during 2020, AMMF's CEO attended weekly virtual NHS cancer charity briefing meetings in order to provide the clearest possible information to those who approached the charity for help. AMMF's Medical and Clinical Advisors were also contacted on a regular basis, to gain an overview of the difficulties that they were experiencing in being able to care for their CCA patients, and for advice on how best to handle the patient queries the charity was receiving.

The Patient Support area of AMMF's website was updated to include a section for COVID-19 advice for CCA patients, with links to appropriate NHS and Government information, and this was updated on a regular basis. Helpful information was also disseminated across AMMF's social media channels whenever possible.

The general areas of AMMF's website continue to be updated regularly, providing information on all aspects of cholangiocarcinoma, including treatments and specialists, and on the advances being made. There is an area specifically for patients and their families, including a discussion forum, 'Our CC Family' and 'Helpful Links', and importantly, there is a comprehensive list of the clinical trials that are available and recruiting in the UK, which is proving a valuable resource to medics and patients.

The charity's active social media platforms kept supporters up to date with information of importance and relevance to them throughout the year. AMMF's Facebook page now has over 5,000 followers, and the following on both Twitter and Instagram continues to grow.

The requirement from individual patients and family members for specific information regarding specialist consultants and treatments continues to increase. With the wider awareness of the charity, increasing incidence and growing recognition of cholangiocarcinoma, it is anticipated this area of work will continue to increase.

**In summary**

2020 has been a very difficult year but, despite the unforeseen problems, the charity has continued to expand its reach and influence nationally and internationally. AMMF is the UK's only cholangiocarcinoma charity and, although by its nature will remain a niche charity, is now firmly established in the UK, Europe and beyond.

As we enter 2021, we look forward with some caution because of the ongoing problems of the pandemic but, with the help of our loyal fundraisers and supporters who have been steadfastly with us throughout this year, AMMF remains fully committed to working towards a far better future for those diagnosed with cholangiocarcinoma.

**FINANCIAL REVIEW**

**Financial review and reserves policy**

The charity has continued to strengthen its financial position during the year.

The charity ensures that sufficient reserves are retained in an appropriate form to fund its current obligations.

Where specific research projects have been secured, the trustees designate sufficient unrestricted reserves to cover the expected future grants payable over the term of the research project.

**AMMF  
(THE ALAN MOREMENT MEMORIAL FUND)**

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31 JANUARY 2021**

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

Approved by order of the board of trustees on 12 November, 2021 and signed on its behalf by:



.....  
Mr N Corrigan - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF  
AMMF  
(THE ALAN MOREMENT MEMORIAL FUND)**

**Independent examiner's report to the trustees of AMMF (The Alan Morement Memorial Fund)**

I report to the charity trustees on my examination of the accounts of AMMF (The Alan Morement Memorial Fund) (the Trust) for the year ended 31 January 2021.

**Responsibilities and basis of report**

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

**Independent examiner's statement**

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ACCA which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Paul Thain BA (Hons) FCCA  
ACCA  
Haslers  
Chartered Accountants  
Old Station Road  
Loughton  
Essex  
IG10 4PL

Date: 22 November 2021

**AMMF**  
**(THE ALAN MOREMENT MEMORIAL FUND)**

**STATEMENT OF FINANCIAL ACTIVITIES**  
**FOR THE YEAR ENDED 31 JANUARY 2021**

	Notes	Unrestricted general fund £	Unrestricted research projects £	Restricted research funds £	2021 Total funds £	2020 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>						
Donations and legacies	2	421,717	-	17,688	439,405	454,119
Other trading activities	3	5,108	-	-	5,108	6,843
Investment income	4	1,146	-	-	1,146	1,357
Other income		<u>10,000</u>	<u>-</u>	<u>-</u>	<u>10,000</u>	<u>-</u>
<b>Total</b>		437,971	-	17,688	455,659	462,319
<b>EXPENDITURE ON</b>						
Raising funds	5	138,917	-	-	138,917	247,242
<b>Charitable activities</b>	6					
Grants Payable		260,035	-	-	260,035	240,808
<b>Total</b>		<u>398,952</u>	<u>-</u>	<u>-</u>	<u>398,952</u>	<u>488,050</u>
<b>NET INCOME/(EXPENDITURE)</b>		39,019	-	17,688	56,707	(25,731)
<b>RECONCILIATION OF FUNDS</b>						
<b>Total funds brought forward</b>		<u>360,065</u>	<u>-</u>	<u>3,432</u>	<u>363,497</u>	<u>389,228</u>
<b>TOTAL FUNDS CARRIED FORWARD</b>		399,084	-	21,120	420,204	363,497

**AMMF  
(THE ALAN MOREMENT MEMORIAL FUND)**

**BALANCE SHEET  
31 JANUARY 2021**

		Unrestricted general fund £	Unrestricted research projects £	Restricted research funds £	2021 Total funds £	2020 Total funds £
<b>FIXED ASSETS</b>						
Tangible assets	11	857	-	-	857	2,003
<b>CURRENT ASSETS</b>						
Stocks	12	5,355	-	-	5,355	5,281
Prepayments and accrued income		10,816	-	-	10,816	6,724
Cash at bank and in hand		<u>386,816</u>	<u>-</u>	<u>21,120</u>	<u>407,936</u>	<u>355,737</u>
		402,987	-	21,120	424,107	367,742
<b>CREDITORS</b>						
Amounts falling due within one year	13	(4,760)	-	-	(4,760)	(6,248)
<b>NET CURRENT ASSETS</b>		<u>398,227</u>	<u>-</u>	<u>21,120</u>	<u>419,347</u>	<u>361,494</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<u>399,084</u>	<u>-</u>	<u>21,120</u>	<u>420,204</u>	<u>363,497</u>
<b>NET ASSETS</b>		<u>399,084</u>	<u>-</u>	<u>21,120</u>	<u>420,204</u>	<u>363,497</u>
<b>FUNDS</b>	15					
Unrestricted funds:						
Unrestricted general fund					399,084	360,065
Restricted funds:						
Restricted research funds					<u>21,120</u>	<u>3,432</u>
<b>TOTAL FUNDS</b>					<u>420,204</u>	<u>363,497</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 12 November, 2021 and were signed on its behalf by:



.....  
Mr N Corrigan - Trustee

**AMMF  
(THE ALAN MOREMENT MEMORIAL FUND)**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 JANUARY 2021**

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

The Alan Morement Memorial Fund is an unincorporated charity. The principal office is detailed on page 1 of the financial statements. The financial statements are presented in Sterling which is the functional currency of the charity. The financial statements comply with section 1A of FRS 102.

**Income**

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

**Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - 33% on cost

**Stocks**

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. Stock is recorded on a first in, first out basis.

**Taxation**

The charity is exempt from tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. The trustees may at their discretion designate a portion of unrestricted funds for a particular purpose. Such designation is a means to set aside funds for that purpose and is not binding on the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**AMMF**  
**(THE ALAN MOREMENT MEMORIAL FUND)**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 JANUARY 2021**

**1. ACCOUNTING POLICIES - continued**

**Operating leases**

Leases where substantially all the risks and rewards incidental to ownership are retained by the lessors are classified as operating leases. Payments made under operating leases are recognised in the Statement of Financial Activities on a straight-line basis over the period of the lease.

**Pension costs and other post-retirement benefits**

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

**2. DONATIONS AND LEGACIES**

	<b>Unrestricted funds</b>	<b>Restricted funds</b>	<b>2021 Total funds</b>	<b>2020 Total funds</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Donations and fundraising	392,114	17,688	409,802	424,653
Gift aid	<u>29,603</u>	<u>-</u>	<u>29,603</u>	<u>29,466</u>
	<u>421,717</u>	<u>17,688</u>	<u>439,405</u>	<u>454,119</u>

**3. OTHER TRADING ACTIVITIES**

	<b>Unrestricted funds</b>	<b>Restricted funds</b>	<b>2021 Total funds</b>	<b>2020 Total funds</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Shop income	<u>5,108</u>	<u>-</u>	<u>5,108</u>	<u>6,843</u>

**4. INVESTMENT INCOME**

	<b>Unrestricted funds</b>	<b>Restricted funds</b>	<b>2021 Total funds</b>	<b>2020 Total funds</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Deposit account interest	<u>1,146</u>	<u>-</u>	<u>1,146</u>	<u>1,357</u>

**5. RAISING FUNDS**

**Raising donations and legacies**

	<b>Unrestricted funds</b>	<b>Restricted funds</b>	<b>2021 Total funds</b>	<b>2020 Total funds</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Support costs	<u>131,431</u>	<u>-</u>	<u>131,431</u>	<u>240,554</u>

An analysis of support costs is shown in note 8 below.

**AMMF  
(THE ALAN MOREMENT MEMORIAL FUND)**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 JANUARY 2021**

**5. RAISING FUNDS - continued**

**Other trading activities**

	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
Shop stock purchases	7,135	-	7,135	6,234
Fundraising	<u>351</u>	<u>-</u>	<u>351</u>	<u>454</u>
	<u>7,486</u>	<u>-</u>	<u>7,486</u>	<u>6,688</u>
Aggregate amounts	<u>138,917</u>	<u>-</u>	<u>138,917</u>	<u>247,242</u>

**6. CHARITABLE ACTIVITIES COSTS**

	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
Research grants	<u>82,432</u>	<u>-</u>	<u>82,432</u>	<u>107,398</u>

**7. GRANTS PAYABLE**

	2021 £	2020 £
Grants Payable	<u>260,035</u>	<u>240,808</u>

All grants were paid to institutions.

The individual grant awards are detailed in the Trustees report.

**8. SUPPORT COSTS**

	Management £	Finance £	Totals £
Raising donations and legacies	<u>130,859</u>	<u>572</u>	<u>131,431</u>

Support costs, included in the above, are as follows:

	2021 Raising donations and legacies £	2020 Total activities £
Wages	64,546	91,000
Social security	1,282	4,913
Pensions	608	1,400
Equipment leasing	2,982	2,982
Operating lease - office rent & service charges	26,472	28,546
Rates and water	<u>1,634</u>	<u>1,595</u>
Carried forward	<u>97,524</u>	<u>130,436</u>

**AMMF  
(THE ALAN MOREMENT MEMORIAL FUND)**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 JANUARY 2021**

**8. SUPPORT COSTS - continued**

	2021 Raising donations and legacies £	2020  Total activities £
Brought forward	97,524	130,436
Insurance	529	481
Marketing and advertising	5,284	29,374
Telephone	3,162	3,156
Postage and stationery	3,984	6,129
Computer and website support	10,249	6,986
Travel	1,870	7,871
Subscriptions	1,230	1,207
Sundries	23	372
Training	50	80
Depreciation of computer equipment	1,146	1,144
Professional fees	2,934	2,126
Conference expenses	2,874	50,346
Bank charges	572	846
	<u>131,431</u>	<u>240,554</u>

**9. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31 January 2021 nor for the year ended 31 January 2020.

**Trustees' expenses**

No trustee expenses were incurred in the year to 31 January 2021 nor for the year to 31 January 2020.

**10. STAFF COSTS**

	2021 £	2020 £
Wages and salaries	64,546	91,000
Social security costs	1,282	4,913
Other pension costs	608	1,400
	<u>66,436</u>	<u>97,313</u>

The average monthly number of employees during the year was as follows:

	2021	2020
Management and administration	<u>3</u>	<u>4</u>

No employees received emoluments in excess of £60,000.

**AMMF**  
**(THE ALAN MOREMENT MEMORIAL FUND)**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 JANUARY 2021**

**11. TANGIBLE FIXED ASSETS**

**Computer  
equipment  
£**

**COST**

At 1 February 2020 and  
31 January 2021

10,305

**DEPRECIATION**

At 1 February 2020

8,302

Charge for year

1,146

At 31 January 2021

9,448

**NET BOOK VALUE**

At 31 January 2021

857

At 31 January 2020

2,003

**12. STOCKS**

**2021**

**2020**

£

£

Goods for resale

5,355

5,281

**13. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

**2021**

**2020**

£

£

Taxation and social security

2,164

1,057

Other creditors

2,596

5,191

4,760

6,248

**14. LEASING AGREEMENTS**

Minimum lease payments under non-cancellable operating leases fall due as follows:

**2021**

**2020**

£

£

Between one and five years

15,546

18,528

**15. MOVEMENT IN FUNDS**

	<b>At 1/2/20</b>	<b>Net movement in funds</b>	<b>At 31/1/21</b>
	£	£	£
<b>Unrestricted funds</b>			
Unrestricted general fund	360,065	39,019	399,084
<b>Restricted funds</b>			
Restricted research funds	3,432	17,688	21,120
<b>TOTAL FUNDS</b>	<u>363,497</u>	<u>56,707</u>	<u>420,204</u>

**AMMF**  
**(THE ALAN MOREMENT MEMORIAL FUND)**

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31 JANUARY 2021**

**15. MOVEMENT IN FUNDS - continued**

Net movement in funds, included in the above are as follows:

	<b>Incoming resources £</b>	<b>Resources expended £</b>	<b>Movement in funds £</b>
<b>Unrestricted funds</b>			
Unrestricted general fund	437,971	(398,952)	39,019
<b>Restricted funds</b>			
Restricted research funds	17,688	-	17,688
	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS</b>	<u>455,659</u>	<u>(398,952)</u>	<u>56,707</u>

**Comparatives for movement in funds**

	<b>At 1/2/19 £</b>	<b>Net movement in funds £</b>	<b>At 31/1/20 £</b>
<b>Unrestricted funds</b>			
Unrestricted general fund	388,719	(28,654)	360,065
<b>Restricted funds</b>			
Restricted research funds	509	2,923	3,432
	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS</b>	<u>389,228</u>	<u>(25,731)</u>	<u>363,497</u>

Comparative net movement in funds, included in the above are as follows:

	<b>Incoming resources £</b>	<b>Resources expended £</b>	<b>Movement in funds £</b>
<b>Unrestricted funds</b>			
Unrestricted general fund	449,396	(478,050)	(28,654)
<b>Restricted funds</b>			
Restricted research funds	12,923	(10,000)	2,923
	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS</b>	<u>462,319</u>	<u>(488,050)</u>	<u>(25,731)</u>

**AMMF  
(THE ALAN MOREMENT MEMORIAL FUND)**

**NOTES TO THE FINANCIAL STATEMENTS - continued  
FOR THE YEAR ENDED 31 JANUARY 2021**

**15. MOVEMENT IN FUNDS - continued**

A current year 12 months and prior year 12 months combined position is as follows:

	At 1/2/19 £	Net movement in funds £	At 31/1/21 £
<b>Unrestricted funds</b>			
Unrestricted general fund	388,719	10,365	399,084
<b>Restricted funds</b>			
Restricted research funds	509	20,611	21,120
	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS</b>	<u>389,228</u>	<u>30,976</u>	<u>420,204</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
Unrestricted general fund	887,367	(877,002)	10,365
<b>Restricted funds</b>			
Restricted research funds	30,611	(10,000)	20,611
	<hr/>	<hr/>	<hr/>
<b>TOTAL FUNDS</b>	<u>917,978</u>	<u>(887,002)</u>	<u>30,976</u>

Restricted funds represent donations where the donor has requested that their donation be used for research purposes only. These donations are held within restricted funds until used in part or in whole to fund a cholangiocarcinoma research project which the charity has committed to supporting.

Designated funds represent amounts set aside at the Trustees' discretion, to fund future instalments of research projects which are to be undertaken over a number of years. Details of the individual research projects are explained in the Trustees' Report.

**16. RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31 January 2021.

**AMMF**  
**(THE ALAN MOREMENT MEMORIAL FUND)**

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES**  
**FOR THE YEAR ENDED 31 JANUARY 2021**

	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
<b>INCOME AND ENDOWMENTS</b>				
<b>Donations and legacies</b>				
Donations and fundraising	392,114	17,688	409,802	424,653
Gift aid	<u>29,603</u>	<u>-</u>	<u>29,603</u>	<u>29,466</u>
	421,717	17,688	439,405	454,119
<b>Other trading activities</b>				
Shop income	5,108	-	5,108	6,843
<b>Investment income</b>				
Deposit account interest	1,146	-	1,146	1,357
<b>Other income</b>				
Discretionary grant award	<u>10,000</u>	<u>-</u>	<u>10,000</u>	<u>-</u>
<b>Total incoming resources</b>	437,971	17,688	455,659	462,319
<b>EXPENDITURE</b>				
<b>Other trading activities</b>				
Shop stock purchases	7,135	-	7,135	6,234
Fundraising	<u>351</u>	<u>-</u>	<u>351</u>	<u>454</u>
	7,486	-	7,486	6,688
<b>Charitable activities</b>				
Grants to institutions	260,035	-	260,035	240,808
<b>Support costs</b>				
<b>Management</b>				
Wages	64,546	-	64,546	91,000
Social security	1,282	-	1,282	4,913
Pensions	608	-	608	1,400
Equipment leasing	2,982	-	2,982	2,982
Operating lease - office rent and service charges	26,472	-	26,472	28,546
Rates and water	1,634	-	1,634	1,595
Insurance	529	-	529	481
Marketing and advertising	5,284	-	5,284	29,374
Telephone	3,162	-	3,162	3,156
Postage and stationery	3,984	-	3,984	6,129
Computer and website support	10,249	-	10,249	6,986
Travel	1,870	-	1,870	7,871
Subscriptions	1,230	-	1,230	1,207
Sundries	23	-	23	372
Carried forward	123,855	-	123,855	186,012

**AMMF  
(THE ALAN MOREMENT MEMORIAL FUND)**

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31 JANUARY 2021**

	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
<b>Management</b>				
Brought forward	123,855	-	123,855	186,012
Training	50	-	50	80
Depreciation of computer equipment	1,146	-	1,146	1,144
Professional fees	2,934	-	2,934	2,126
Conference expenses	<u>2,874</u>	<u>-</u>	<u>2,874</u>	<u>50,346</u>
	130,859	-	130,859	239,708
<b>Finance</b>				
Bank charges	<u>572</u>	<u>-</u>	<u>572</u>	<u>846</u>
Total resources expended	<u>398,952</u>	<u>-</u>	<u>398,952</u>	<u>488,050</u>
<b>Net (expenditure)/income</b>	<u>39,019</u>	<u>17,688</u>	<u>56,707</u>	<u>(25,731)</u>